Physician profile
Paul Kelly
NPI 1346242831
$825.67
in general payments reported to CMS, 2019-2025
15 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2021: $17.48 · 2022: $36.55 · 2023: $130 · 2024: $91.33 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $215.32 | 2019 | |
| Inspire Medical Systems, INC. | $165.20 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $72.17 | 2019-2025 | Nucala |
| Intersect Ent, INC. | $58.66 | 2019 | |
| Optinose US, INC. | $54.78 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
| Phathom Pharmaceuticals, INC. | $41.74 | 2025 | Voquezna |
| Genzyme Corporation | $36.55 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $23.95 | 2024 | |
| Kaleo, INC. | $22.86 | 2019 | |
| Philips North America LLC | $21.14 | 2019 | |
| Allergan, INC. | $18.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.88 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $13.83 | 2019 | |
| Csl Behring | $13.53 | 2025 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.